期刊文献+

女性生殖道癌肉瘤37例临床及预后分析 被引量:3

Clinical and prognosis analysis of 37 cases of carcinosarcomas in female reproductive tract
下载PDF
导出
摘要 目的对37例女性生殖道癌肉瘤的诊断、治疗及预后进行分析。方法对1996年-2006年复旦大学附属妇产科医院住院手术治疗的37例女性生殖道癌肉瘤的临床、病理和预后资料进行回顾性分析。结果37例癌肉瘤中Ⅰ期15例、Ⅱ期9例、Ⅲ期11例、Ⅳ期2例。Ⅰ-Ⅱ期、Ⅲ-Ⅳ期的3年总生存率分别为84.6%、33.3%,差异有统计学意义(P=0.007)。对恶性腺体和间叶组织来源、淋巴结转移、肌层浸润深度(仅对子宫癌肉瘤)、脉管浸润、p53基因表达、年龄(分<60岁和≥60岁2组)、妊娠次数(分≤4次和>4次2组)、是否化疗放疗与预后的关系进行统计学分析。单因素分析表明,肌层浸润深度(P=0.006)、脉管浸润(P=0.046)、年龄(P=0.027)、妊娠次数(P=0.047)与预后有关;多因素分析表明,对于子宫癌肉瘤,年龄(P=0.033)和肌层浸润深度(P=0.027)与预后有关。对于所有癌肉瘤,淋巴结转移(P=0.022)和p53基因表达(P=0.032)与预后有关。结论女性生殖道癌肉瘤患者的预后可能与年龄、肌层浸润深度、淋巴结转移、脉管浸润、妊娠次数及p53基因表达等有关。加强对绝经后妇女的妇科超声普查对早发现生殖道癌肉瘤有一定的意义。 Objective To investigate the diagnosis,treatment and prognosis of carcinosarcomas(CS)in female reproductive tract.Methods Thirty-seven cases of CS treated in our hospital between 1996-2006 were reviewed.The clinico-pathologic characteristics,treatment and prognosis were retrospectively analyzed.Results The overall survival for patients with stage Ⅰ-Ⅱ and stage Ⅲ-Ⅳ was 84.6% and 33.3%(P=0.007),respectively.Patients'myometrial invasion,vessel invasion,age and times of pregnancy were associated with prognosis by univariate analysis(P〈0.05),while in a multivariate analysis age and myometrial invasion were associated with prognosis(P〈0.05)in the uterine CS and lymph node metastasis and the expression of p53 were associated with prognosis(P〈0.05)in all CS.Conclusions The prognosis of CS were associated with age,myometrial invasion,lymph node metastasis,vessel invasion,times of pregnancy and the expression of p53.It's useful for the early diagnosis of CS by ultrasonography for the menopausal women.
出处 《复旦学报(医学版)》 CAS CSCD 北大核心 2008年第2期199-203,共5页 Fudan University Journal of Medical Sciences
基金 上海市重点科建设项目资助(编号:B117)
关键词 癌肉瘤 诊断 治疗 预后 carcinosarcomas diagnosis treatment prognosis
  • 相关文献

参考文献13

  • 1Stanley J,Malcolm C,Peter Russell,主编.回允中主译.女性生殖病理学[M].北京:北京大学医学出版社,2005,375-380.
  • 2Hughes V, Reed N. The association between tamoxifen and uterine carcinasarcoma[J]. EJC Suppl,2004,2(9) :85.
  • 3Joseph P. Connor. Aggressive of the uterine cervix associates with high levels of granulocyte colony stimulating factor: Case report and laboratory correlates[J]. Gynecol Oncol, 2006,103 ( 1 ) :349 - 353.
  • 4Joseph M, Vladirnir K, Tally L,et al. Expression of c-kit in uterine carcinosarcoma[J]. Gynecol Oncol, 2005,96 ( 1 ) : 210 -215.
  • 5Teresa L, Michael A,Scott M. Carcinosarcoma of the ovary-a case series[J]. Gynecol Oncol,2006,100(1) : 128- 132.
  • 6John P, John A, John T. Paclitaxel in the Treatment of Carcinosarcoma of the Uterus: A Gynecologic Oncology Group Study[J]. Gynecol Oncol, 2001,83( 1 ) : 268 - 270.
  • 7Masafumi T, Jun A, Gen M. Clinical experience with combination paclitaxel and carboplatin therapyfor advanced or recurrent carcinosarcoma of the uterus [J]. Gynecol Oncol,2004,94(3) :774- 778.
  • 8Gregory S, James K, Linda F. Adjuvant ifosfamide and cisplatin in patients with completely resected stage Ⅰ or Ⅱ carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study [J]. Gynecol Oncol, 2005,96 (3) : 630 - 634.
  • 9R. E.N. van Rijswijka, JB. Vermorkenb, N. Reedc. Cispla tin, doxorubicin and ifosfamide in of the female genital tract. A phase II study of the European Organizationfor Research and Treatment of Cancer Gynaecological Cancer Group (EORTC 55923) [J ]. Eur J Cancer, 2003,39 (4) :481 - 487.
  • 10J. Tate T, John A. Blessing, b Koen DeGeest. Cisplatin as initial chemotherapy in ovarian carcinosarcomas: a Gynecologic Oncology Group Study[J] . Gynecol Oncol, 2004, 93 (2) : 336 - 339.

同被引文献39

  • 1宁燕,周先荣,朱慧庭,王丽,曲玉清,朱勤,杨立峰.子宫癌肉瘤26例临床病理及预后影响因素分析[J].临床与实验病理学杂志,2007,23(5):520-523. 被引量:13
  • 2Cimbaluk D, Rotmensch J, Scudiere J,et al. Uterine studies on tissue microarrays with focus on potential therapeutic targets [ J ]. Gynecol Oncol, 2007,105 ( 1 ) : 138-144.
  • 3Pardo J, Aisa G, Alava ED, et al. Primary mixed squamous carci-noma and osteosarcom(carcinosarcoraas) of the lung have a CGH mapping similar to primitive squamous carcinomas and osteosarco- mas [ J ]. Diagn Mol Pathol,2008,17 (3) : 151-158.
  • 4Armstrong AB, Wang M, Eble JN, et al. TP53 mutation alanalysis supports monoclonal origin of biphasic sarcomatoid urothelial carci- noma (careinosarcoma) of the urinary bladder [ J ]. 2009,22(1) :113-118.
  • 5Garg G, Shah JP, Kumar S, et al. Ovarian and uterine Mod Pathol mas:a comparative analysis of prognostic variables and survival outcomes[ J]. Int J Gynecol Cancer,2010,20 (5) :888-894.
  • 6Bansal N, Herzoq TJ, Seshan VE, et al. Uterine carcinosarcomas and grade 3 endometrioid cancers evidence for distinct tumor behavior[J]. Bosket Gyneeo1,2008,112 ( 1 ) :64-70.
  • 7Kuyumcuoglu U, Kale A. Homologous type of malignant mixed Mullerian tumor of the uterus presenting as a cervical mass [ J ]. J Chin Med Assoc,2009,72(10) :533-535.
  • 8Arora P, Ran S, Khurana N, et al. Malignant mixed Mullerian tumor of broad ligament with synchronous ovarian and endometrial carci- noma: a rare association [ J ]. J Cancer Res Ther, 2011,7 ( 1 ) : 88-91.
  • 9Kato H, Kanematsu M, Furui T, et al. C of the ute- rus : radiologie-pathologic correlations with magnetic resonance ima- ging including diffusion- weighted imaging [ J ]. Magn Reson Ima- ging,2008,26 (10) : 1446-1450.
  • 10Gonzalea Bosquet J, Terstriep SA, Clihy WA, et al. The impact of multi-modal therapy on survival for uterine carcinosarcoma [ J ]. Gvnecol Oncol.2010.116 ( 3 ) :419-423.

引证文献3

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部